CONGRESS ABSTRACT

Background: There's increasing evidence on the possible pro-atherogenic side effect of immune checkpoint inhibitors (ICIs) leading to an increased risk of atherosclerotic cardiovascular disease (ASCVD) in long-term treated patients. Methods: We retrospectively collected data on acute coronary syndrome (ACS) in active cancer patients receiving ICIs for more than 6…

A 71-year-old man with a family history of dilated cardiomyopathy (CMD) and a history of dual-chamber pacemaker implantation for sick sinus syndrome was diagnosed with HER2-positive metastatic adenocarcinoma of the distal esophagus. He was selected for treatment with FOLOFOX chemotherapy (CT) and Trastuzumab. Due to the potential cardiotoxicity associated…

Introduction: Emerging evidence suggests that patients with coronary artery disease carry an increased risk of cancer death. Methods: To assess the association between heart failure (HF) during hospitalization with acute coronary syndrome (ACS) and the very long-term cancer death risk, we enrolled 571 patients admitted with ACS to 3 Italian hospitals…

Introduction: Recent studies have indicated that sodium-glucose cotransporter-2 inhibitors (SGLT2i) may possess cardioprotective properties, providing dual benefits for patients in cardio-oncology. However, their specific effects on reducing the risk of hospitalization for heart failure (HF) in patients with type 2 diabetes mellitus (T2DM) undergoing anticancer treatments remain to be…

A 87-year-old woman presented at ED with typical chest pain and SARS-COV2 infection. Past medical history included multiple myeloma treated with Lenalidomide/Daratumumab (started in the previous 15 days) and previous bioprosthetic aortic valve replacement. The initial ECG showed sinus tachycardia, LFB and "lambda-like" ST-segment elevation in the precordial leads…

Background: Recent meta analyzes have highlighted the key role of oxLDL in cardiovascular risk in patients with/without cancer through the stimulation of pro-inflammatory signaling. GLP-1 receptor agonists, like semaglutide, have shown cardiorenal benefits in patients with/without diabetes, proposing themselves as a new cardioprotective strategy in a broad patient setting….

We describe the clinical case of an 82-year-old woman with a history of breast cancer treated with quadrantectomy and subsequent adjuvant chemotherapy three years earlier, which was interrupted early due to an episode of cardiac toxicity manifested by congestive heart failure and a moderate reduction in ejection fraction. The…

Introduction: Breast cancer is the most common type of cancer worldwide. Heart failure (HF) is a complex clinical syndrome caused by a structural or functional heart disorder. Patients with heart failure have increased risk for adverse cardiac events following non-cardiac Surgery.   Material and Methods We report the experience of our breast surgery unit….

Background: Combining anthracyclines and trastuzumab is highly effective in treating HER2-positive breast cancer but significantly increases the risk of cardiotoxicity. The sequential approach is often preferred, where anthracyclines are given first, followed by trastuzumab, with careful monitoring of heart function. Purpose: We report for the first time the cardioprotective…

Cardiac angiosarcoma is a rare endothelial cell tumor, the most common primary malignant tumor of the heart, characterized by an aggressive permeating growth within the surrounding myocardial wall. In most cases, it occurs in the right atrium and can infiltrate into neighboring structures and spread distantly. It is associated…